Applied Spectral Imaging Launches Two New Products for the Digital Pathology Market
Had a chance to see get a sneak peek of this back in April when I visited with the company in Israel. ASI, a global leader in the development and sale of computer aided imaging solutions for cytogenetics, pathology and the life sciences offers advanced end-to-end automated solutions for the detection, capture and analysis of regions of interest, driving greater efficiencies and increasing throughput and employee productivity, compared to other existing technologies.
Now, at CAP 2017 they will be unveiling two more products — PathFusion and HiPathPro that combines their efficient workflow solutions as well as whole slide imaging! Visit them at booth #805 if you are attending CAP in Maryland this week!
Applied Spectral Imaging (ASI), a global leader in computer-assisted biomedical imaging, announced today the launch of PathFusion™ and HiPath Pro™, innovative Brightfield and FISH imaging & analysis solutions for pathology. ASI will unveil the new products at the upcoming CAP 2017 meeting in Maryland, October 8-10, 2017.
PathFusion by ASI for advanced digital pathology (Applied Spectral Imaging (ASI))
The PathFusion system is a cutting-edge workflow solution, bridging the gap between Brightfield pathology and FISH. Combining microscope-based Whole Slide Imaging, industry-leading Tissue FISH applications and revolutionary digital tissue matching of FISH with H&E/IHC samples, it provides accurate and validated analysis for higher diagnostic confidence. Powered by GenASIs, PathFusion supports a wide range of sample types, IHC antibodies and FISH probes, and features modern digital workflows that increase laboratory productivity and improve FTE savings.
HiPath Pro is a unique Brightfield imaging & analysis system for a variety of histopathology needs, including Whole Slide Imaging of H&E/IHC samples and Quantitative IHC Scoring of membrane and nuclear stains. Through exceptional image quality and precise computer-assisted analysis, it provides uncompromising results standardization, in addition to streamlining communication and simplifying sharing processes. The HiPath Pro manual configuration is FDA cleared for IHC Family HER2/neu, ER, PR and Ki-67.
“We are excited to introduce these new breakthrough technologies, demonstrating once again our relentless commitment to advancing patient diagnostics”, said Limor Shiposh, CEO of ASI. “PathFusion and HiPath Pro, both powered by our proprietary GenASIs algorithms, address the most pressing needs of modern pathology laboratories: digital workflows that increase productivity, labor efficiencies, data accessibility and above all, standardized results through accurate, consistent analysis.”
Visit the ASI booth #805 at the CAP 2017 meeting to learn more.
About ASI
ASI is a global leader in the development of biomedical imaging solutions, supporting fluorescent, Brightfield and spectral image-acquisition, for the Pathology and Cytogenetics markets.
HiPath Pro™ and PathFusion™, powered by GenASIs™, are automated imaging platforms that provide advanced diagnostic aids for pathologists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any laboratory.
ASI’s applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.
ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.
www.appliedspectralimaging.com/digitalpathology
Source: Applied Spectral Imaging
